# Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis

> **NCT05555303** · PHASE2 · UNKNOWN · sponsor: **Rwanda Biomedical Centre** · enrollment: 20 (estimated)

## Conditions studied

- Tuberculosis, Multidrug-Resistant

## Interventions

- **DRUG:** Amikacin

## Key facts

- **NCT ID:** NCT05555303
- **Lead sponsor:** Rwanda Biomedical Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2024-03
- **Final completion:** 2026-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05555303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05555303, "Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05555303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*